

Publications 2005

- Lagaraine, C., C. Hoarau, V. Chabot, F. Velge-Roussel, and Y. Lebranchu. 2005. Mycophenolic acid-treated human dendritic cells have a mature migratory phenotype and inhibit allogeneic responses via direct and indirect pathways. *Int Immunol* 17:351;
- Beaudreuil, S., G. Lasfargues, L. Laueriere, Z. El Ghoul, F. Fourquet, C. Longuet, J. M. Halimi, H. Nivet, and M. Buchler. 2005. Occupational exposure in ANCA-positive patients: a case-control study. *Kidney Int* 67:1961 ;
- Bourgoin, H., G. Paintaud, M. Buchler, Y. Lebranchu, E. Autret-Leca, F. Mentre, and C. Le Guellec. 2005. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. *Br J Clin Pharmacol* 59:18;
- Buchler, M., Y. Lebranchu, M. Beneton, Y. Le Meur, A. E. Heng, P. F. Westeel, C. le Guellec, F. Libert, L. Hary, P. Marquet, and G. Paintaud. 2005. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. *Clin Pharmacol Ther* 78:34;
- Buchler, M., and A. Johnston. 2005. Seeking optimal prescription of cyclosporine ME. *Ther Drug Monit* 27:3.
- Dragon-Durey, M. A., C. Loirat, S. Cloarec, M. A. Macher, J. Blouin, H. Nivet, L. Weiss, W. H. Fridman, and V. Fremeaux-Bacchi. 2005. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 16:555;
- Giral, M., J. M. Nguyen, G. Karam, M. Kessler, B. Hurault de Ligny, M. Buchler, F. Bayle, C. Meyer, Y. Foucher, M. L. Martin, P. Daguin, and J. P. Souillou. 2005. Impact of graft mass on the clinical outcome of kidney transplants. *J Am Soc Nephrol* 16:261;
- Halimi, J. M., I. Laouad, M. Buchler, A. Al-Najjar, V. Chatelet, T. S. Houssaini, H. Nivet, and Y. Lebranchu. 2005. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. *Am J Transplant* 5:2281;
- Laouad, I., J. M. Halimi, M. Buchler, A. Al-Najjar, V. Chatelet, H. Nivet, and Y. Lebranchu. 2005. Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: analysis of long-term follow-up in renal transplantation. *Transplantation* 80:872;
- Laouad, I., M. Buchler, C. Noel, T. Sadek, H. Maazouz, P. F. Westeel, and Y. Lebranchu. 2005. Renal artery aneurysm secondary to *Candida albicans* in four kidney allograft recipients. *Transplant Proc* 37:2834. Laouad, I., M. Buchler, P. F. Weestel, Y. Lebranchu, C. Legendre, G. Choukroun, and E. Thervet. 2005. Replacement kidney lipomatosis after renal transplantation. Lebranchu, Y., J. M. Halimi, A. Bock, J. Chapman, B. Dussol, L. Fritsche, V. Kliem, F. Oppenheimer, E. Pohanka, M. Salvadori, M. Soergel, and G. Tufveson. 2005. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. *Transplant Proc* 37:345.
- Legendre, C., S. M. Beard, A. Crochard, Y. Lebranchu, C. Pouteil-Noble, A. Richter, and I. Durand-Zaleski. 2005. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. *Eur J Health Econ*.
- Nathanson, S., P. Cochat, J. L. Andre, C. Guyot, C. Loirat, H. Nivet, and G. Deschenes. 2005. Recurrence of nephrotic syndrome after renal transplantation: influence of increased Premaud, A., J. Debord, A. Rousseau, Y. Le Meur, O. Toupance, Y. Lebranchu, G. Hoizey, C. Le Guellec, and P. Marquet. 2005. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. *Clin Pharmacokinet* 44:837;
- Proust, A., B. Guillet, I. Pellier, P. Rachieru, C. Hoarau, S. Claeysens, C. Leonard, S. Charrier, W. Vainchenker, G. Tchernia, and J. Delaunay. 2005. Recurrent V75M mutation within the Wiskott-Aldrich syndrome protein: description of a homozygous female patient. *Eur J Haematol* 75:54;
- Salvadori, M., A. Bock, J. Chapman, B. Dussol, L. Fritsche, V. Kliem, Y. Lebranchu, F. Oppenheimer, E. Pohanka, G. Tufveson, A. Rosati, X. Puig, and G. Corbetta. 2005. Impact of mycophenolate mofetil dose posttransplantation on 12-month renal function: analysis of the MOST database. *Transplant Proc* 37:2464 ;
- Stefoni, S., K. Midtved, E. Cole, E. Thervet, S. Cockfield, M. Buchler, L. Toselli, L. M. Pallardo, F. P. Schena, H. Pilmore, M. Kessler, S. Chadban, and C. A. Carreno. 2005. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. *Transplantation* 79:577 ;